S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

GRF Eagle Capital Growth Fund Inc

9.4456

0.00 (0.00%)

Last Updated: 12:16:39

Delayed by 15 minutes

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Eagle Capital Growth Charts.

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Eagle Capital Growth Charts.

Eagle Capital Growth Fund Inc News

Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.
Thursday 18 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening
Thursday 4 April 2024 (1 month ago) • GlobeNewswire Inc.

Form DEF 14A - Other definitive proxy statements
Thursday 7 March 2024 (2 months ago) • Edgar (US Regulatory)

Form N-CSR - Certified Shareholder Report
Wednesday 6 March 2024 (2 months ago) • Edgar (US Regulatory)

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 23 February 2024 (2 months ago) • Edgar (US Regulatory)

Grifols announces positive topline phase 3 fibrinogen clinical trial results
Wednesday 14 February 2024 (3 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 13 February 2024 (3 months ago) • Edgar (US Regulatory)

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
Wednesday 15 November 2023 (6 months ago) • GlobeNewswire Inc.

Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)
Tuesday 7 November 2023 (6 months ago) • Edgar (US Regulatory)

More Eagle Capital Growth Fund Inc News Articles

Brookmount Explorations (PK)

Ronn Motor (PK)

Kraig Biocraft Laborator... (QB)

1812 Brewing (PK)

Innovation Pharmaceuticals (CE)

Ecare Solutions (PK)

Globestar Therapeutics (PK)

MicroCloud Hologram

Kona Gold Beverage (PK)

Auto Parts 4Less (PK)

Clean Vision (QB)

Indoor Harvest (PK)

Elite Pharmaceuticals (QB)

Bioelectronics (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions